KALA BIO, Inc.
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical d… Read more
KALA BIO, Inc. (0JQ2) - Net Assets
Latest net assets as of September 2025: $-8.66 Million USD
Based on the latest financial reports, KALA BIO, Inc. (0JQ2) has net assets worth $-8.66 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($25.02 Million) and total liabilities ($33.69 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-8.66 Million |
| % of Total Assets | -34.63% |
| Annual Growth Rate | 45.32% |
| 5-Year Change | -87.67% |
| 10-Year Change | N/A |
| Growth Volatility | 499.42 |
KALA BIO, Inc. - Net Assets Trend (2013–2024)
This chart illustrates how KALA BIO, Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for KALA BIO, Inc. (2013–2024)
The table below shows the annual net assets of KALA BIO, Inc. from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $12.33 Million | +64.34% |
| 2023-12-31 | $7.50 Million | -60.45% |
| 2022-12-31 | $18.97 Million | +12.91% |
| 2021-12-31 | $16.80 Million | -83.20% |
| 2020-12-31 | $100.00 Million | +236.77% |
| 2019-12-31 | $29.69 Million | -71.72% |
| 2018-12-31 | $104.99 Million | +17.07% |
| 2017-12-31 | $89.68 Million | +202.18% |
| 2016-12-31 | $-87.76 Million | -1414.97% |
| 2015-12-31 | $-5.79 Million | -277.59% |
| 2014-12-31 | $3.26 Million | +1514.85% |
| 2013-12-31 | $202.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to KALA BIO, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 64499300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.00K | 0.05% |
| Other Components | $680.25 Million | 5516.10% |
| Total Equity | $12.33 Million | 100.00% |
KALA BIO, Inc. Competitors by Market Cap
The table below lists competitors of KALA BIO, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GHST World Inc
PINK:GHST
|
$1.97 Million |
|
Birks Group Inc
NYSE MKT:BGI
|
$1.97 Million |
|
Trillium Gold Mines Inc
OTCQX:TGLDF
|
$1.97 Million |
|
Verena Multi Finance Tbk
JK:VRNA
|
$1.97 Million |
|
Monumental Minerals Corp
OTCQB:MNMRF
|
$1.97 Million |
|
REPUBLIC SERVICES - Dusseldorf Stock Exchang
DU:RPU
|
$1.96 Million |
|
HOUSTON AMERN ENE.DL-001
F:8H6H
|
$1.96 Million |
|
American Copper Development Corporation
OTCQB:ACDXF
|
$1.96 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in KALA BIO, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 7,504,000 to 12,332,000, a change of 4,828,000 (64.3%).
- Net loss of 38,511,000 reduced equity.
- Other factors increased equity by 43,339,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-38.51 Million | -312.29% |
| Other Changes | $43.34 Million | +351.44% |
| Total Change | $- | 64.34% |
Book Value vs Market Value Analysis
This analysis compares KALA BIO, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.11x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.57x to 0.11x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $0.42 | $0.24 | x |
| 2014-12-31 | $6.74 | $0.24 | x |
| 2015-12-31 | $-16.76 | $0.24 | x |
| 2016-12-31 | $-253.89 | $0.24 | x |
| 2017-12-31 | $210.76 | $0.24 | x |
| 2018-12-31 | $196.21 | $0.24 | x |
| 2019-12-31 | $43.40 | $0.24 | x |
| 2020-12-31 | $95.46 | $0.24 | x |
| 2021-12-31 | $12.89 | $0.24 | x |
| 2022-12-31 | $12.48 | $0.24 | x |
| 2023-12-31 | $3.09 | $0.24 | x |
| 2024-12-31 | $2.23 | $0.24 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently KALA BIO, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -312.29%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 4.50x
- Recent ROE (-312.29%) is above the historical average (-696.63%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -5273.76% | -21306.00% | 0.01x | 35.01x | $-10.67 Million |
| 2014 | -593.53% | -4255.16% | 0.04x | 3.59x | $-19.69 Million |
| 2015 | 0.00% | -37071.11% | 0.01x | 0.00x | $-16.10 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-24.39 Million |
| 2017 | -47.07% | 0.00% | 0.00x | 1.29x | $-51.18 Million |
| 2018 | -63.57% | 0.00% | 0.00x | 2.10x | $-77.24 Million |
| 2019 | -317.75% | -1553.29% | 0.04x | 5.20x | $-97.32 Million |
| 2020 | -104.33% | -1639.85% | 0.03x | 2.22x | $-114.33 Million |
| 2021 | -848.64% | -1268.73% | 0.08x | 8.30x | $-144.29 Million |
| 2022 | -236.23% | -1151.64% | 0.04x | 4.58x | $-46.72 Million |
| 2023 | -562.35% | 0.00% | 0.00x | 7.46x | $-42.95 Million |
| 2024 | -312.29% | 0.00% | 0.00x | 4.50x | $-39.74 Million |
Industry Comparison
This section compares KALA BIO, Inc.'s net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| KALA BIO, Inc. (0JQ2) | $-8.66 Million | -5273.76% | N/A | $1.97 Million |
| Nyfosa AB (0A0K) | $2.92 Billion | 39.50% | 2.88x | $973.31 Million |
| High Templar Tech Limited (0A2T) | $12.52 Billion | 4.70% | 0.13x | $255.82 Million |
| Strategy Inc (0A7O) | $51.04 Billion | -7.54% | 0.21x | $40.17 Billion |
| NACON SASU (0A9N) | $67.54 Million | 15.85% | 1.20x | $7.64 Million |
| Antin Infrastructure Partners (0AA5) | $23.79 Million | 108.98% | 1.09x | $573.10 Million |
| Truecaller AB Series B (0AA7) | $1.41 Billion | 18.30% | 0.20x | $281.60 Million |
| Brockhaus Technologies AG (0AAW) | $254.92 Million | -6.23% | 1.68x | $74.40 Million |
| Hyloris Pharmaceuticals S.A. (0AB6) | $48.06 Million | -24.09% | 0.32x | $71.96 Million |
| Kalray S.A. (0ABT) | $28.43 Million | -41.56% | 0.67x | $33.84 Million |
| Webuild S.p.A. (0BJP) | $1.43 Billion | 10.29% | 7.14x | $1.13 Billion |